www.fdanews.com/articles/142679-exelixis-licenses-pi3k-delta-inhibitor-r-amp-d-program-to-merck

Exelixis Licenses PI3K-Delta Inhibitor R&D Program to Merck

December 21, 2011

Exelixis licensed its PI3K-delta research and development program to Merck in order to focus on its lead compound cabozantinib, a potential cancer treatment.
The Wall Street Journal